Press Enter to search · Esc to close
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
Two fresh analyses push the GLP-1 conversation past nausea, flagging ear-nose-throat signals and a higher risk of failed bowel prep. Here's what tired parents juggling a new prescription actually need to know.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
As weekly injections become a fixture of the looksmaxing toolkit, anesthesiologists are raising a quieter alarm about what happens when patients carrying a slow-emptying stomach meet an operating table.
A fresh systematic review consolidates the perioperative signals — delayed gastric emptying, hypoglycemia, anesthesia risk — that every patient on a GLP-1 should bring up before surgery.
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.